Q-omics provides the consensus-scored ELOA profile across patient tissues and cancer cell-line models. ELOA expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ELOA is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ELOA protein abundance shows 25,099 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, and PDAC as cancer lineages where ELOA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOA survival associations across molecular data types. ELOA RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOA RNA expression–survival associations across cancer types. High ELOA expression shows unfavorable associations in KICH, KIRP, ACC, CESC and LGG, but favorable associations in KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ELOA RNA expression.
This table summarizes ELOA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ELOA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOA shows lower tumor expression in KICH, THCA, LUAD and KIRP and higher tumor expression in BLCA and HNSC. The KICH box plot shows higher ELOA RNA expression in normal versus tumor tissue (log2 FC = −1.253, t-test p < 0.001).
This table shows molecular features associated with ELOA in patient tissues and cancer cell lines. In patient samples, ELOA shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ELOA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
